Clinical Trial Detail

NCT ID NCT03016871
Title Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors City of Hope Medical Center

Hodgkin's lymphoma


Carboplatin + Etoposide + Ifosfamide + Nivolumab

Age Groups: adult senior child

Additional content available in CKB BOOST